StockData
Co-Diagnostics, Inc. logo

Co-Diagnostics, Inc. (CODX) stock

CODXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.28−0.01 (-3.78%)

Close on Nov 11, 2026Market cap $1.74MP/E –Yield –

Earnings

Co-Diagnostics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 30, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$166.13K
-16.9% on a year earlier
EPS, Q2 FY2026
-$1.46
-$0.23 a year earlier
Latest guidance
Issued
Mar 24, 2022 · 4 items

Quarterly results

Revenue and earnings per share from each of Co-Diagnostics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 30, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026before the open–––Release
Q2 FY2026ended Jun 30, 2026Aug 13, 2026after the close$166.13K-16.9%-$1.46Release
Q1 FY2026ended Mar 31, 2026May 14, 2026after the close$150.00K+50.0%-$4.06Release
Q4 FY2025ended Dec 31, 2025Mar 31, 2026after the close–––Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025after the close$100.00K-83.3%-$0.16Release
Q2 FY2025ended Jun 30, 2025Aug 14, 2025after the close$200.00K-92.6%-$0.23Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close$100.00K-80.0%-$0.24Release
Q4 FY2024ended Dec 31, 2024Mar 27, 2025after the close–––Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close$600.00K-76.0%–Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024after the close$2.70M+1250.0%-$0.25Release
Q1 FY2024ended Mar 31, 2024May 9, 2024after the close$500.00K-16.7%-$0.31Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Co-Diagnostics guided for has been reported

Guidance vs results

The last range Co-Diagnostics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q1 FY2022EPS (GAAP)$0.17 – $0.20$0.34Above range
Q1 FY2022Revenue$21.00M – $22.00M$22.70MAbove range

Guidance history

Every forecast Co-Diagnostics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Mar 24, 2022Adjusted EBITDAQ1 FY2022$9.00M – $10.00MNew
Mar 24, 2022Diluted EPSQ1 FY2022$0.17 – $0.20New
Mar 24, 2022Diluted shares outstandingQ1 FY202232.4New
Mar 24, 2022revenueQ1 FY2022$21.00M – $22.00MNew
Nov 12, 2021Diluted earnings per shareFY2021$1.07 – $1.16New
Nov 12, 2021corporate effective tax rateFY202118%New
Nov 12, 2021shares outstandingFY202130New
Nov 12, 2021RevenueFY2021$96.00M – $100.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Co-Diagnostics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Reports Third Quarter 2026 Financial Results
    Results
  2. 8-K exhibit EX-99.1
    Update
  3. to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola
    News
  4. Reports Second Quarter 2026 Financial Results
    Results
  5. Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
    News
  6. Reports First Quarter 2026 Financial Results
    Results
  7. Reports Full Year 2025 Financial Results
    Results
  8. LAKE CITY, Dec. 30, 2025 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx” or “the Company”),
    Update
  9. Reports Third Quarter 2025 Financial Results
    Results
  10. Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
    News
  11. Inc. to Participate in the Lytham
    Update
  12. Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
    News
  13. Inc. Reports Second Quarter 2025 Financial Results
    Results
  14. Inc. Reports First Quarter 2025 Financial Results
    Results
  15. have entered into the Amended and Restated Equity Distribution Agreement dated April 25, 2025, with Piper Sandler and Clear Street LLC
    News

See a number that looks wrong?